Aspen Neuroscience Announces First Patient Dosed in First-in-Human Phase 1/2a Clinical Trial of Autologous Neuronal Cell Replacement Therapy for Parkinson’s Disease
First U.S. Multi-center, Multi-patient Phase 1/2a Trial of an Autologous Neurological Therapy SAN DIEGO, April 17, 2024 /PRNewswire/ — Aspen Neuroscience, Inc. announced that the first patient has been dosed in the ASPIRO trial, a Phase 1/2a open label clinical trial to assess safety and tolerability of ANPD001, an autologous, dopaminergic neuron cell replacement therapy for participants with moderate
Learn MoreDr. Lisa Johnson-Pratt Joins Aspen Neuroscience as Senior Vice President, Therapeutic Program Lead
SAN DIEGO, Feb. 14, 2024 /PRNewswire/ — Aspen Neuroscience, Inc., a private biotechnology company developing induced Pluripotent Stem Cell (iPSC)-derived cell therapies, announced that Lisa Johnson-Pratt, MD has joined the company’s executive management team in a new role as Senior Vice President, Therapeutic Program Lead. An industry leader with more than 25 years of experience, Dr. Johnson-Pratt will
Learn MoreAspen Neuroscience Appoints Ana Sousa Chief Regulatory Officer
SAN DIEGO, Jan. 16, 2024 /PRNewswire/ — Aspen Neuroscience, Inc., a private biotechnology company developing the first autologous neuron replacement therapies to treat Parkinson’s disease (PD), announced today the appointment of Ana Sousa, MSJ as the company’s Chief Regulatory Officer. Since 2021, Ms. Sousa has served as Senior Vice President of Regulatory and Quality at Aspen, where she developed the regulatory,
Learn MoreAspen Neuroscience to Present at Future of Parkinson’s Disease Conference
SAN DIEGO and AUSTIN, Texas, Nov. 30, 2023 /PRNewswire/ — This week, Aspen Neuroscience will present to the Parkinson’s community at the Future of Parkinson’s Disease conference, held November 30 – December 3, in Austin. The joint annual conference is hosted by the Parkinson’s Foundation and the Parkinson Study Group. In addition to multiple scientific presentations, Aspen Chief Executive Officer Damien McDevitt, PhD, and co-founder and
Learn MoreAspen Neuroscience Cofounder Dr. Andrés Bratt-Leal Receives 2023 Biocom California Life Science Catalyst Award
SAN DIEGO, CALIF., November 21, 2023 – Biocom California, the association representing the California life sciences industry, has announced that Andrés Bratt-Leal, PhD, Aspen Neuroscience co-founder and senior vice-president of research and development, is a recipient of the 2023 Life Science Catalyst Awards. The winners will be honored in the Biocom California LifeLines digital platform,
Learn MoreFDA Grants Fast Track Designation to ANPD001, Autologous Investigational Cell Therapy for the Treatment of Parkinson’s Disease
SAN DIEGO, Oct. 19, 2023 /PRNewswire/ — Aspen Neuroscience today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for ANPD001 for the treatment of Parkinson’s disease (PD) to improve motor function. ANPD001, is a personalized (autologous) cell therapy under investigation to treat PD by replacing lost dopamine neurons. The purpose of Fast
Learn MoreAspen Neuroscience to Partner with Rune Labs and Emerald Innovations to Incorporate both Active and Passive Digital Health Monitoring in Trial Ready Cohort Screening Study
Screening Study to Include Multiple Objective Measures of Active and Passive Symptom Capture from Parkinson’s Disease Impact on Motor Function SAN DIEGO, Aug. 24, 2023 /PRNewswire/ — Aspen Neuroscience today announced that it is partnering with Emerald Innovations, a pioneer in the creation of “invisible” off-body sensors for measuring health analytics, and Rune Labs, a software and
Learn MoreAspen Neuroscience Announces FDA Clearance of Investigational New Drug Application for ANPD001, Autologous Cell Therapy for the Treatment of Parkinson’s Disease
Aspen Will Initiate First Multicenter Phase 1/2a Clinical Trial of an Autologous iPSC Based Therapy in the U.S. SAN DIEGO, Aug. 8, 2023 /PRNewswire/ — Aspen Neuroscience today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application, enabling the company to proceed with a clinical trial for ANPD001, a personalized
Learn MorePreclinical Safety and Efficacy Data for ANPD001 Presented by Dr. Andres Bratt-Leal at 2023 World Parkinson Congress in Barcelona
SAN DIEGO, July 6, 2023 /PRNewswire/ — On Wednesday at the 2023 World Parkinson Congress in Barcelona, Aspen Neuroscience co-founder Andres Bratt-Leal, PhD, Senior Vice President Research & Development, presented preclinical safety and efficacy data for the first time for ANPD001, Aspen’s iPSC-derived lead candidate for treatment of Parkinson’s Disease (PD). Dr. Bratt-Leal’s poster presentation, “Preclinical Safety and Efficacy of Dopamine
Learn MoreDr. Andres Bratt-Leal to Present Preclinical Safety and Efficacy Data for ANPD001 at the 2023 World Parkinson Congress in Barcelona
SAN DIEGO, June 29, 2023 /PRNewswire/ — Next week at the upcoming World Parkinson Congress (WPC) 2023 in Barcelona, Spain, Aspen Neuroscience co-founder Andres Bratt-Leal, PhD, Senior Vice President, Research and Development, will present preclinical safety and efficacy data for the first time for ANPD001, Aspen’s iPSC-derived lead candidate for treatment of Parkinson’s Disease (PD). “Preclinical Safety and Efficacy of Dopamine
Learn MoreDr. Andrés Bratt-Leal to Present at the 2023 International Society for Stem Cell Research Annual Meeting Focus Sessions
SAN DIEGO, June 14, 2023 /PRNewswire/ — Today Aspen Neuroscience, Inc. co-founder and Senior Vice President, Research & Development, Andrés Bratt-Leal, PhD, will present “Enabling Autologous iPSC-Derived Cell Therapies with Predictive Genomics,” during the Focus Sessions taking place during this week’s 2023 International Society for Stem Cell Research (ISSCR) Annual Meeting in Boston, Mass. His presentation will cover experiences
Learn MoreAspen Neuroscience Inks $40 Million Debt Deal with Silicon Valley Bank
SAN DIEGO Calif., December 21, 2022 — Aspen Neuroscience, Inc., a private biotechnology company developing autologous cell therapies including the first iPSC-derived autologous neuron replacement treatment for Parkinson’s disease (PD), has signed a $40 million credit facility with Silicon Valley Bank (SVB). Deal terms were not disclosed.“We are pleased to work with Silicon Valley Bank.
Learn MoreCMC Expert Kim Raineri Joins Aspen Neuroscience as Chief Technology Officer
SAN DIEGO, Oct. 19, 2022 – Aspen Neuroscience, Inc., a private biotechnology company developing the first autologous neuron replacement therapies to treat Parkinson’s disease (PD), announced that Kim Raineri has joined the company as Chief Technology Officer and as a member of the company’s executive team.
Learn MoreDr. Xiaokui Zhang to Present Aspen Neuroscience, Inc. at 2022 Cell & Gene on the Mesa
SAN DIEGO, Oct. 11, 2022 — This week Xiaokui Zhang, Ph.D., Chief Scientific Officer of Aspen Neuroscience, Inc. will present at the 2022 Cell & Gene Meeting on the Mesa Conference in Carlsbad, Calif. including presenting a live corporate update and participating in a panel session to highlight new developments in the induced pluripotent stem cell (iPSC) field. This
Learn MoreNeuriTest™ Presented Publicly for the First Time at the International Society for Stem Cell Research Annual Meeting
SAN DIEGO, June 22, 2022 — Aspen Neuroscience, Inc. Director of Bioinformatics, Roy Williams, Ph.D., presented NeuriTest™ for the first time publicly last week at the 2022 International Society for Stem Cell Research (ISSCR) Annual Meeting in San Francisco, Calif. Dr. Williams’ podium presentation, “NeuriTest: A Bioinformatics-based Tool for Quality Control of iPSC-derived Dopamine Neuron Precursors for Transplantation,” featured the advanced
Learn MoreAspen Neuroscience Announces $147.5 Million Series B Financing, Led by GV, LYFE Capital and Revelation Partners
Will Fund Clinical Trials of Company’s First iPSC-derived Autologous Dopamine Neuron Replacement for Parkinson’s Disease FOR IMMEDIATE RELEASE CONTACT:Angelyn Lowemedia@aspenneuro.com SAN DIEGO, Calif., May 9, 2022 — Aspen Neuroscience, Inc., a private biotechnology company developing autologous cell therapies, including the first iPSC-derived autologous neuron replacement treatment for Parkinson’s disease (PD), today announced the close of
Learn MoreAspen Neuroscience Launches First Patient Screening Study for Planned Clinical Trial of Personalized Cell Replacement in Parkinson’s Disease
SAN DIEGO, Calif., April 12, 2022 — Aspen Neuroscience, Inc., a private biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies, including the first autologous neuron replacement for Parkinson’s disease (PD), announced that this month it will launch the first patient screening study of its kind, working with multiple clinical screening sites in the
Learn MoreScientific Leader Xiaokui Zhang, Ph.D. Joins Aspen Neuroscience as Chief Scientific Officer
SAN DIEGO, Calif., November 18, 2021 — Aspen Neuroscience, Inc., a private biotechnology company developing the first autologous neuron replacement therapies to treat Parkinson’s disease (PD), announced that Xiaokui Zhang, Ph.D., has joined the company as Chief Scientific Officer and as a member of the company’s executive team. With 20 years of progressive biopharmaceutical industry
Learn MoreIndustry Veteran Kameel Farag Joins Aspen Neuroscience as Chief Financial Officer
SAN DIEGO, Calif., Nov. 9, 2021 — Aspen Neuroscience, Inc., a private biotechnology company developing the first autologous neuron replacement therapies to treat Parkinson’s disease (PD), announced that Kameel Farag has joined the company as Chief Financial Officer and as a member of the company’s executive team
Learn MoreRegulatory Affairs Expert Ana Sousa Joins Aspen Neuroscience as Senior Vice President
SAN DIEGO, July 12, 2021 — Aspen Neuroscience, Inc., a private biotechnology company developing the first autologous neuron replacement therapies to treat Parkinson’s disease (PD), announced today that Ana Sousa has joined the company as senior vice president of regulatory affairs and quality, and as a member of the company’s executive team. “Ana’s extensive regulatory
Learn More